NCT00888472

Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma

Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Patients With Refractory Asthma

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Gunma University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Extracorporeal leukocytapheresis (LCAP) or granulocytapheresis (GCAP) has been used in the treatment of patients with rheumatoid arthritis and ulcerative colitis and has shown promising safety and efficacy. LCAP and GCAP seem to be effective for steroid-resistant inflammation. The investigators have already reported safety and efficacy of GCAP in refractory asthma and expect the beneficial effect of LCAP in refractory asthma. In this study, in order to improve the therapeutic effect of LCAP by increasing the quantity of leukocytes that were removed, the investigators conducted a clinical study to investigate safety and efficacy of high-dose LCAP performed using a larger filter and an increased dose of the blood volume per body weight treated, as an possible therapy for refractory asthma.

Conditions

• Bronchial Asthma

Interventions

Type	Name	Description
PROCEDURE	Leukocytapheresis	5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.

Timeline

• Start date: 2008-11-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2009-04-27
• Last updated: 2019-02-15

Locations

1 site across 1 country: Japan